frame-graph02ttt01Overall1.800.20.40.60.811.21.41.6PlaceboXyzalP<0.001Improvement in RQLQQoL_Chart1_All_m[1]OverallPlaceboXyzalP<0.0011.800.20.40.60.811.21.41.6Improvement in RQLQ37%improvementvs placebo (P<0.001)Vector Smart ObjectNasalSymptomsEyeSymptoms**PlaceboXyzal*P<0.001;P<0.051.800.20.40.60.811.21.41.6Improvement in RQLQQoL_Chart1_All_m[1]*P<0.001;P<0.05PlaceboXyzalNasalSymptomsEyeSymptoms**1.800.20.40.60.811.21.41.6Improvement in RQLQVector Smart Object2ActivitiesSleepPracticalProblemsEmotional**PlaceboXyzal*P<0.001;P<0.051.800.20.40.60.811.21.41.6Improvement in RQLQQoL_Chart1_All_m[1]ActivitiesSleepPracticalProblemsEmotional**1.800.20.40.60.811.21.41.6*P<0.001;P<0.05PlaceboXyzalImprovement in RQLQttt02Improvement in WPAI-AS Scores20181614121086420Patient Xperience20181614121086420ctaObject1LevocetirizineXyzalvs.LevocetirizineXyzal 5 mgLevocetirizineDextrocetirizineZyrtec 10 mgvs.Xyzal 5 mgLevocetirizineDextrocetirizineZyrtec 10 mgLevocetirizinesymptom-xpert-graph00-desktop-50-40-30-20-100Xyzal(n=240)Xyzal(n=236)!"!#!$!"#$()*+,-./,01-50-40-30-20-100Percent Reduction in MSCS with XyzalXyzal(n=240)Xyzal(n=236)46%reduction vs 11% placebo (n=93) (P<0.001)34% reduction vs 18% placebo (n=95) (P<0.001)Hour 1Hour 24Week 8Mean T4SS Change from BaselineWeek 10-0.5-1-1.5-2-2.5-3-3.5-4PlaceboXyzalVector Smart Object4PlaceboXyzalWeek 1Week 80-0.5-1-1.5-2-2.5-3-3.5-486%Reductionvs placebo(P<0.001)47%Reductionvs placebo(P<0.001)Mean T4SS Change from Baseline0 -0.5 -1 -1.5 -2 -2.5 -3 -3.5 -4symptom-xpert-graph02-desktopWeek 100.20.40.60.81.06 MonthsMean T5SS Change from BaselineXyzalPlacebo6 MonthsWeek 1PlaceboXyzal00.20.40.60.81.06 MonthsMean T5SS Change from BaselineWeek 16 Months00.20.40.60.81.0PlaceboXyzalMean T5SS Change from BaselineWeek 16 MonthsPlaceboXyzal00.20.40.60.81.0Mean T5SS Change from BaselineWeek 16 MonthsPlaceboXyzal00.20.40.60.81.0Mean T5SS Change from BaselineSignificant Reduction in Symptoms14121086420-2-101 25 26 27 28Mean Score (MSCS)24PlaceboXyzal 5 mg (P<0.001)Hours After Drug IntakeSignificant Reduction in Symptoms

For U.S. Healthcare Professionals Only

Now available OTC

A smart Formulation is NOW a Wise OTC Choice for Allergy Sutters


Wisely Designed to Be Different

Active enantiomer of Zyrtec®with no dextrocetirizine1

The clinical relevance regarding the absence of dextrocetirizine is unknown.


Discover True 24

Powerful Relief That Doesn’t Fade2


Potent Medicine. Powerful Relief.1

Patient Xperience And More

Footnotes & References
x
  • References: 1. Xyzal [prescribing information]. Smyrna, GA: UCB, Inc.; 2016. 2. Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol. 2005;60(1):24-31.

A Smart Formulation Is NOW a Wise
OTC Choice for Allergy Sufferers

Wisely Designed
to Be Different

Active enantiomer of Zyrtec®
with no dextrocetirizine1

Active enantiomer of Zyrtec with no dextrocetirizine

The clinical relevance regarding the absence of dextrocetirizine is unknown.

Discover True 24

Powerful Relief That Doesn’t Fade2

Discover True 24: Powerful relief that doesn't fade

Potent Medicine.
Powerful Relief.1

Patient Xperience
And More

Delivers allergy relief that patients need
Footnotes & References
x
  • References: 1. Xyzal [prescribing information]. Smyrna, GA: UCB, Inc.; 2016. 2. Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol. 2005;60(1):24-31.